Prof Ingrid Scheffer discusses COVID-19 and issues relevant to children and adults with genetic epilepsy / DEEs and their families.
Mutations of the SCN2A gene can result in a range of different clinical syndromes. Understanding these clinical presentations can help to guide treatment.
Prof Steven Petrou and Dr Kiran Reddy discuss the RC-222 program developing an ASO treatment for gain-of-function SCN2A epilepsies.
When Alex Nemiroff's son was born, he was determined to work towards finding treatments for SCN2A, and is now CEO of RogCon with a treatment in development.
Natural History Studies (NHS) are important in planning trials of treatment. We talk with Dr Katherine Howell, principal investigator of the SCN2A NHS.
Prof Ingrid Scheffer has published many key papers in SCN2A and genetic epilepsies and discusses the progress that has been made in understanding SCN2A.